MX2016004551A - Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis. - Google Patents
Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.Info
- Publication number
- MX2016004551A MX2016004551A MX2016004551A MX2016004551A MX2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- atherosclerosis
- treatment
- binding molecules
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Se proporcionan en la presente métodos para reducir, inhibir, suprimir y/o retrasar el crecimiento de placa aterosclerótica o neovascularización en un sujeto que tiene aterosclerosis, que comprende administrar al sujeto una cantidad efectiva de una molécula de ligación aislada que se liga específicamente a Semaforina-4D (SEMA4D) o a su receptor Plexina-B1 de alta afinidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361889421P | 2013-10-10 | 2013-10-10 | |
PCT/US2014/060129 WO2015054628A1 (en) | 2013-10-10 | 2014-10-10 | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004551A true MX2016004551A (es) | 2016-07-22 |
Family
ID=52809873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004551A MX2016004551A (es) | 2013-10-10 | 2014-10-10 | Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9512224B2 (es) |
EP (1) | EP3054976B1 (es) |
JP (2) | JP6760840B2 (es) |
KR (1) | KR102366682B1 (es) |
CN (1) | CN105848679A (es) |
AU (1) | AU2014331683B2 (es) |
BR (1) | BR112016008010A2 (es) |
CA (1) | CA2926944C (es) |
DK (1) | DK3054976T3 (es) |
EA (1) | EA037551B1 (es) |
ES (1) | ES2821814T3 (es) |
IL (1) | IL244976B (es) |
MX (1) | MX2016004551A (es) |
NZ (1) | NZ630881A (es) |
PT (1) | PT3054976T (es) |
SG (1) | SG11201602807PA (es) |
WO (1) | WO2015054628A1 (es) |
ZA (1) | ZA201602577B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108912228B (zh) | 2009-05-08 | 2022-03-15 | 瓦西尼斯公司 | 抗-cd100抗体和其使用方法 |
EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
MX2015017485A (es) | 2013-06-25 | 2016-03-31 | Vaccinex Inc | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
RU2759846C2 (ru) | 2016-04-22 | 2021-11-18 | Вэксинекс, Инк. | Дисплей интегрального мембранного белка на внеклеточных оболочечных вирионах поксвируса |
WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
CN106474559B (zh) * | 2016-11-30 | 2019-07-12 | 西南交通大学 | 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法 |
JP2020510845A (ja) * | 2017-02-22 | 2020-04-09 | バクシネックス インコーポレーティッド | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 |
CN106983919B (zh) * | 2017-03-06 | 2019-07-12 | 西南交通大学 | 一种Sema 4D-VEGF涂层的构建方法及应用 |
KR20200004324A (ko) | 2017-05-05 | 2020-01-13 | 백시넥스 인코포레이티드 | 인간 항-세마포린 4d 항체 |
CN108499220B (zh) * | 2018-04-25 | 2020-07-31 | 山东纯江环境科技有限公司 | 石墨烯/聚丙烯非织造布过滤网制备方法及其应用 |
CN109125731B (zh) * | 2018-10-22 | 2019-10-25 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 |
KR20230135556A (ko) * | 2020-06-25 | 2023-09-25 | 백시넥스 인코포레이티드 | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 |
CN116949097B (zh) * | 2023-09-20 | 2023-12-12 | 江苏集萃药康生物科技股份有限公司 | 一种sema4d人源化小鼠模型的构建方法及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
SI1773885T1 (sl) | 2004-08-05 | 2010-08-31 | Genentech Inc | Humanizirani anti-CMET antagonisti |
US20060147449A1 (en) * | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
WO2006110594A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Sema4d in cancer diagnosis, detection and treatment |
JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
AR070134A1 (es) | 2008-01-10 | 2010-03-17 | Genentech Inc | Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso |
CN108912228B (zh) | 2009-05-08 | 2022-03-15 | 瓦西尼斯公司 | 抗-cd100抗体和其使用方法 |
CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
JP5925768B2 (ja) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | 骨形成促進剤 |
EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
US9090709B2 (en) * | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
MX2015017485A (es) | 2013-06-25 | 2016-03-31 | Vaccinex Inc | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
-
2014
- 2014-09-11 NZ NZ630881A patent/NZ630881A/en unknown
- 2014-10-10 CN CN201480067853.5A patent/CN105848679A/zh active Pending
- 2014-10-10 CA CA2926944A patent/CA2926944C/en active Active
- 2014-10-10 US US14/511,679 patent/US9512224B2/en active Active
- 2014-10-10 ES ES14853023T patent/ES2821814T3/es active Active
- 2014-10-10 WO PCT/US2014/060129 patent/WO2015054628A1/en active Application Filing
- 2014-10-10 BR BR112016008010A patent/BR112016008010A2/pt not_active Application Discontinuation
- 2014-10-10 EA EA201690728A patent/EA037551B1/ru unknown
- 2014-10-10 EP EP14853023.1A patent/EP3054976B1/en active Active
- 2014-10-10 PT PT148530231T patent/PT3054976T/pt unknown
- 2014-10-10 MX MX2016004551A patent/MX2016004551A/es unknown
- 2014-10-10 AU AU2014331683A patent/AU2014331683B2/en active Active
- 2014-10-10 KR KR1020167012123A patent/KR102366682B1/ko active IP Right Grant
- 2014-10-10 DK DK14853023.1T patent/DK3054976T3/da active
- 2014-10-10 SG SG11201602807PA patent/SG11201602807PA/en unknown
- 2014-10-10 JP JP2016521774A patent/JP6760840B2/ja active Active
-
2016
- 2016-04-07 IL IL244976A patent/IL244976B/en active IP Right Grant
- 2016-04-15 ZA ZA201602577A patent/ZA201602577B/en unknown
-
2019
- 2019-02-28 JP JP2019035055A patent/JP2019108359A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3054976A1 (en) | 2016-08-17 |
AU2014331683B2 (en) | 2019-07-11 |
DK3054976T3 (da) | 2020-09-28 |
ZA201602577B (en) | 2020-11-25 |
AU2014331683A1 (en) | 2016-04-28 |
IL244976A0 (en) | 2016-05-31 |
CN105848679A (zh) | 2016-08-10 |
SG11201602807PA (en) | 2016-05-30 |
EA037551B1 (ru) | 2021-04-13 |
EP3054976B1 (en) | 2020-07-08 |
CA2926944A1 (en) | 2015-04-16 |
BR112016008010A2 (pt) | 2017-09-26 |
EP3054976A4 (en) | 2017-05-17 |
KR102366682B1 (ko) | 2022-02-22 |
CA2926944C (en) | 2023-08-08 |
JP2019108359A (ja) | 2019-07-04 |
US20150104462A1 (en) | 2015-04-16 |
US9512224B2 (en) | 2016-12-06 |
KR20160062167A (ko) | 2016-06-01 |
EA201690728A1 (ru) | 2016-08-31 |
PT3054976T (pt) | 2020-08-05 |
IL244976B (en) | 2020-07-30 |
NZ630881A (en) | 2016-03-31 |
JP2016539089A (ja) | 2016-12-15 |
JP6760840B2 (ja) | 2020-09-23 |
WO2015054628A1 (en) | 2015-04-16 |
ES2821814T3 (es) | 2021-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016004551A (es) | Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis. | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
MX347164B (es) | Anticuerpos anti-il-36r. | |
NZ709059A (en) | Immunotherapy with binding agents | |
MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
MX2015017485A (es) | Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis. | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
PH12015501360A1 (en) | Bmp-6 antibodies | |
WO2013013238A3 (en) | Compounds and related compositions and methods of use | |
TN2014000207A1 (en) | Anti il-36r antibodies |